

Who should attend?

The VIII Workshop on Imported Chagas Disease is aimed at all categories of health professionals, including doctors, nurses, biologists, parasitologists, anthropologists, epidemiologists, and health sciences students.

Venue

Casa del Mar de Barcelona - Generalitat de Catalunya
C/ d'Albareda n° 1-13, 08004 Barcelona, Spain. Tel: +34 93 441 48 59

Registration

To register, send an e-mail specifying your **full name, national ID/passport number, workplace, and address** to tallerchagas@cesib.cat.

Simultaneous interpretation services from Spanish to English will be provided. Please let us know if you require these services.

Once your registration has been accepted and your place confirmed, please transfer the appropriate registration fee to the bank account indicated below.

Registration fee and payment details

Registration fees are €80 euro for non-students and €60 euro for students (lunch included). **Bank account: IBAN: ES38 2100 0811 7102 0112 3097 (Caixabank, S.A).**

Please indicate **"Chagas Workshop"** on the bank transfer slip and send a copy by e-mail (tallerchagas@cesib.cat) or fax (+34 93 227 98 53).

Oral Communications and posters

If you are interested in presenting an oral communication or poster, please refer to the accompanying sheet for details. **The deadline for submission is January 10, 2012.**


At least one of the authors of the original paper must register for the workshop.

More information

Centre de Recerca en Salut Internacional de Barcelona
(CRESIB, Hospital Clínic-Universitat de Barcelona)
C/ Roselló 132, 4° 08036 Barcelona (Spain)
Tel: +34 93 227 5400 Ext: 4135 Fax: +34 93 227 98 53
Email: tallerchagas@cesib.cat

VIII WORKSHOP ON IMPORTED CHAGAS DISEASE

Advances in antiparasitic treatment of Chagas disease



5 MARCH 2012
BARCELONA

ISGlobal Barcelona
Institute for
Global Health

 **CRESIB**
BARCELONA
Hospital Clínic - Universitat de Barcelona

Activity approved for **1 credit point** by the Catalan Council
for Continuing Medical Training
(Continuing Training Commission of the National Health
System)
Officially recognised health care-relevant activity




Mundo Sano

Workshop organised with the collaboration
and sponsorship of:



This work has been supported by the EC within the
7th Framework Program under grant agreement no. FP7-GA-261495



Chagas disease, caused by the protozoan parasite *Trypanosoma cruzi*, is endemic in Central and South America. Despite the implementation of vector control programmes and screening measures in blood banks and maternity wards, an estimated 8 million people are infected with *T. cruzi*.

In the past, this parasitic disease mainly affected poor people living in the countryside, but it has become increasingly common in towns and cities due to rural-urban migration. Its prevalence is also increasing in countries that receive immigrants from Chagas disease-endemic countries. In Spain alone, an estimated 50,000 to 68,000 people are infected with *T. cruzi*.

One of the challenges faced by our health care system is to care for and treat patients with Chagas disease. The value of specific antiparasitic treatment is a much debated issue due to the high frequency of adverse effects associated with such treatment and doubts about its effectiveness in patients with chronic disease.

The autoimmunity hypothesis and the lack of early markers of cure are at the heart of the controversy surrounding specific antiparasitic treatment and have put a brake on research and development into new, improved drugs. Nonetheless, the scientific advances made over the last 15 years have opened the door to a paradigm shift.

The VIII Workshop on Imported Chagas Disease will review, expand on, and update our knowledge about antiparasitic treatment and its scientific basis, report on advances made in recent years, and discuss new approaches to the treatment of this neglected disease.

Organising Committee	Scientific Committee
Edelweiss Aldasoro	Pere Albajar
Núria Casamitjana	Maria Jesús Pinazo
Montserrat Gállego	Montserrat Portús
Joaquim Gascon	Isabela Ribeiro
Jordi Gómez i Prat	Sergio Sosa-Estani
Elizabeth Posada	Faustino Torrico
Carme Roca	Rodolfo Viotti

PROGRAMME

- 8:15 - 8:45** **Registration and collection of documents**
- 8:45 - 9:00** **Welcome**
Antoni Plasència, *CRESIB*, Barcelona (Spain)
Representative of *AECID*, (Spain) - to be confirmed
- 9:00 - 9:30** **New evidence on the effectiveness of antiparasitic treatment in chronic Chagas disease**
Rodolfo Viotti, *Hospital Eva Peron*, Buenos Aires (Argentina)
- 9:30 - 10:30** **Update on clinical trials with posaconazole and ravuconazole**
Carlos Morillo, *McMaster University*, Ontario (Canada)
Israel Molina, *Hospital de la Vall d'Hebron*, Barcelona (Spain)
Faustino Torrico, *Universidad Mayor de San Simon*, Cochabamba (Bolivia)
- 10:30 - 11:00** **Oral communications**
- 11:00 - 11:30** **Coffee break**
- 11:30 - 12:30** **Update on the BENEFIT and TRAENA Benznidazole clinical trials**
Adelina Riarte, *Instituto Nacional de Parasitología "Dr. M. Fatała Chabén"*, Buenos Aires (Argentina)
Carlos Morillo, *McMaster University*, Ontario (Canada)
- 12:30 - 13:30** **Population pharmacokinetics of Benznidazole in children and adults**
Jaime Altchek, *Hospital de niños R. Gutierrez*, Buenos Aires (Argentina)
Isabela Ribeiro, *Drugs for Neglected Diseases initiative (DNDi)*, Rio de Janeiro (Brazil)
- 13:30 - 14:30** **Lunch**
- 14:30 - 15:00** **The future: combined antiparasitic treatment for Chagas disease?**
Sergio Sosa-Estani, *Centro de Documentación e Información Educativa (CENDIE)*, Buenos Aires (Argentina)
- 15:00 - 15:15** **Experiences with early diagnosis and prompt treatment in non-endemic areas of Argentina**
Sónia Tarragona, *Mundo Sano Foundation*, Buenos Aires (Argentina)
- 15:15 - 15:30** **Oral communications**
- 15:30 - 16:30** **Challenges regarding the availability of antiparasitic drugs for Chagas disease**
- Distribution network for Benznidazole for chronic Chagas disease in Bolivia
Max Enriquez, *Ministry of Health, National Plan to Combat Chagas Disease*, Cochabamba (Bolivia)
- Availability of pediatric Benznidazole
Isabela Ribeiro, *Drugs for Neglected Diseases initiative (DNDi)*, Rio de Janeiro (Brazil)
- 16:30** **Closing remarks**
Pere Albajar, *World Health Organization (WHO)*, Geneva (Switzerland)
Felipe Guhl, *Universidad de los Andes*, (Colombia)